Esperion is suing its business partner, Daiichi Sankyo, alleging that the Japanese drugmaker wrongly refuses to pay a $300 million milestone owed to the biotech company after reporting data from a giant trial of its cardiovascular drug Nexletol.
The 2019 settlement between the companies required Daiichi Sankyo to pay $150 million upfront, plus an additional $150 million after the first sales of the drug. But another main payment linked to an earnings study published this month, called CLEAR. Daiichi argues that the drug’s more than 20 percent relief from the central attack threat is enough to prompt a $300 million payout from Daiichi once it is added to the drug’s label.
Unlock this story right away and sign up for over 164,400 biopharmaceutical professionals to read Endpoints daily, and it’s free.
Welcome to Endpoints Weekly, your review of this week’s most sensitive biopharmaceutical stocks. Do you want that in your inbox every Saturday morning?Current Endpoint readers can view your drive profile to load Weekly Endpoints. New to Endpoints? Register here.
To date, most, if not all, of you have learned the exciting news that Endpoints has joined the Financial Times family. Thank you for all your years, and now, on more important things!
Unlock this story right away and sign up for over 164,400 biopharmaceutical professionals to read Endpoints daily, and it’s free.
GSK will have to pay royalties to AstraZeneca on total sales of its ovarian cancer drug Zejula, a British court said on Wednesday.
The case dates back to a licensing agreement Tesaro signed with AstraZeneca in 2012, years before GSK bought it for $5. 1 billion, which led to Zejula’s approval in 2017 for recurrent epithelial cancer of the ovarian, fallopian tube or peritoneum number one. The inhibitory PARP has gained a handful of label extensions, adding as first-line maintenance treatment for complex ovarian cancer and as fourth-line treatment, this indication has since been withdrawn.
Unlock this story right away and sign up for over 164,400 biopharmaceutical professionals to read Endpoints daily, and it’s free.
Phlow, the Virginia-based manufacturer, has invested $36 million in its latest investment circular as it looks to develop its production services.
According to a statement, Phlow’s most recent fundraiser will be used to expand its CDMO program, dubbed cdmoX. Its CDMO program is also designed for customers to get regulatory approvals faster, said Robby Demeria, Phlow’s director of corporate affairs.
Unlock this story right away and sign up for over 164,400 biopharmaceutical professionals to read Endpoints daily, and it’s free.
Takeda recently told researchers that it is finishing preclinical studies and studies on the AAV gene treatment, as well as preclinical studies and studies on rare hematology, a spokesperson said in an email to Endpoints News.
The move will not have an effect on the existing clinical progression pipeline or advertising products, the spokesperson said, noting that the number of workers affected has not yet been decided, as it is possible that they will be redistributed to other R spaces.
Unlock this story right away and sign up for over 164,400 biopharmaceutical professionals to read Endpoints daily, and it’s free.
A spin-off company of J
The move comes after a bankruptcy ruling Tuesday rejected an initial attempt through the company, called LTL Management, to use bankruptcy as a means to settle anti-talc lawsuits. The new proposal represents a billion-dollar buildup on top of its previous proposal. of $2 billion. The split of J
Unlock this story right away and sign up for over 164,400 biopharmaceutical professionals to read Endpoints daily, and it’s free.
The first RSV vaccines are getting closer to the truth in what industry executives and analysts anticipate as the start of the next race for successful vaccines that can shape a market value of more than $10 billion.
On Wednesday, Pfizer published two papers in the New England Journal of Medicine detailing the positive effects of the latest late-stage study. An FDA ruling on the vaccine is expected in May, as well as a ruling on competitor GSK’s vaccine. Moderna’s product, still in testing, may compete this year or early next year.
Unlock this story right away and sign up for over 164,400 biopharmaceutical professionals to read Endpoints daily, and it’s free.
A day after obtaining emergency use authorization for its Covid-19 antibody, InflaRx said it had enough source to treat several thousand patients. However, most likely, the drug has a five-figure value.
InflaRx aims to make vilobelimab available as soon as possible, CEO Niels Riedemann said Wednesday on a call with analysts. receiving invasive mechanical ventilation or extracorporeal membrane oxygenation.
Pennsylvania’s Pocono Mountains are more of a tourist destination, but Sanofi is turning a small domain town into a hub for vaccine production.
Sanofi opened a new formula and filling plant at its site in Swiftwater, Pennsylvania, halfway between Philadelphia and Scranton.
The new 32,000-square-foot facility will cost about $160 million, a Sanofi spokesperson told Endpoints News in an email. The site, according to a statement from Sanofi, will be a two-story construction that will fill syringes and vials. The opening of the facility will mark one of the 3 investments BARDA has made in Sanofi to boost domestic production of pandemic influenza vaccines.
Unlock this story right away and sign up for over 164,400 biopharmaceutical professionals to read Endpoints daily, and it’s free.
Arbutus accused Pfizer and BioNTech of infringing on its patents on the generation of lipid nanoparticles in its Covid-19 mRNA-based vaccine.
While Arbutus and Genevant Sciences (partially owned by Arbutus and Vivek Ramaswamy’s Roivant) claimed that Pfizer and BioNTech had created and manufactured their vaccine “at a speed unprecedented in the history of medicine,” the plaintiffs argued in a lawsuit filed Tuesday that the feat has not been imaginable without generation invented by Arbutus scientists “years earlier. “
© Endpoints 2023 News
We will email you a link to set a new password. Please note that this link is for single use and is valid for 24 hours.